Provided by Tiger Trade Technology Pte. Ltd.

TG Therapeutics

54.30
+0.37000.69%
Pre-market: 54.20-0.1000-0.18%06:43 EDT
Volume:1.62M
Turnover:87.45M
Market Cap:8.31B
PE:19.61
High:54.36
Open:53.58
Low:52.67
Close:53.93
52wk High:59.30
52wk Low:26.76
Shares:153.09M
Float Shares:141.54M
Volume Ratio:1.01
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):2.77
ROE:100.28%
ROA:7.28%
PB:13.76
PE(LYR):19.60

Loading ...

TG Therapeutics Announces Publication of Post-Hoc Data From the Phase 3 Ultimate I & Ii Trials in Treatment Naive Patients With Relapsing Forms of MS Published in Frontiers in Immunology

THOMSON REUTERS
·
Jun 01

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

GlobeNewswire
·
Jun 01

Analysts’ Top Healthcare Picks: Pfizer (PFE), TG Therapeutics (TGTX)

TIPRANKS
·
May 28

TG Therapeutics CEO to join Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

TG Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires Live
·
May 27

TG Therapeutics reports ENHANCE trial meets primary endpoint

TIPRANKS
·
May 27

TG Therapeutics Announces Positive Topline Results From Phase 3 Enhance Trial

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Phase 3 Enhance Trial Shows Bioequivalence for Single 600 Mg Day 1 Briumvi Infusion

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Supplemental Bla Filing for Consolidated Briumvi Dosing Targeted for 2H-2026

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Single Infusion Safety Consistent With Established Briumvi Profile

THOMSON REUTERS
·
May 27

TG Therapeutics Inc: Phase 3 Trial Met Its Primary Endpoint

THOMSON REUTERS
·
May 27

TG Therapeutics Inc - Secondary Endpoints Consistent With Prior Studies; No New Safety Signals Observed

THOMSON REUTERS
·
May 27

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

GlobeNewswire
·
May 27

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

GlobeNewswire
·
May 26

How Investors May Respond To TG Therapeutics (TGTX) Boosting 2026 Guidance On Stronger Briumvi Sales

Simply Wall St.
·
May 24

TG Therapeutics Raises 2026 Outlook As Briumvi Drives Concentrated Growth

Simply Wall St.
·
May 22

A Look At TG Therapeutics (TGTX) Valuation After Record Q1 Revenue And Higher 2026 Guidance

Simply Wall St.
·
May 10

TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test

Simply Wall St.
·
May 08

TG Therapeutics price target raised to $70 from $60 at H.C. Wainwright

TIPRANKS
·
May 07